Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natrol sales & earnings

This article was originally published in The Tan Sheet

Executive Summary

Chatsworth, Calif.-based company will continue to invest in its recently launched Annasa network marketing subsidiary and expects to incur $1 mil.-$2 mil. in related expenses until the division reaches cash flow break even point in 2004, according to Natrol's 110-K report filed April 14 with the Securities & Exchange Commission. Firm recorded $6.1 mil. net loss in 2002, including a $6.8 mil. charge related to write off of goodwill from prior acquisitions. Sales fell 2.1% to $70.3 mil. for the year, due primarily to the firm's inability to increase its overall presence within "core mass-market and health food channels of trade" and intentional reduction of "slow moving and unprofitable items," Natrol says...

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by 

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel